News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Client Alert March 11, 2026
Texas Corporate Developments: What Officers and Directors Need to Know in March 2026
Companies and their advisors should continue to monitor these developments closely as they consider how Texas’s evolving corporate ecosystem may …
Firm News March 9, 2026
Gibson Dunn Advised RedBird IMI on Sale of Telegraph Media Group
Gibson Dunn advised RedBird IMI on the £575 million ($767 million) sale of its interests in Telegraph Media Group (TMG) to German-based media group Axel Springer.
Client Alert March 9, 2026
UK Public M&A: The Month in a Minute (February 2026)
Surprise valentine Schroders goes 2.7 official – but for others it was the wrong type of red card in February …
Firm News March 6, 2026
Gibson Dunn Advised Gryphon Investors on Majority Investment in HRSoft
Gibson Dunn advised Gryphon Investors, a San Francisco-based middle-market private investment firm, on its majority investment in HRSoft, a leading provider of enterprise compensation management software based in Denver, Colorado.
Firm News March 3, 2026
Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc.
Firm News March 2, 2026
Gibson Dunn Advises Thmanyah on Media Rights Agreement with Saudi Professional League, Saudi Arabian Football Federation, and First Division League
Gibson Dunn advised Thmanyah Publishing and Distribution Company (Thmanyah), a subsidiary of the Saudi Research and Media Group, on entering into a media rights agreement with the Saudi Professional League, the Saudi Arabian Football Federation, and the First Division League.
Firm News February 27, 2026
Gibson Dunn Advised Shareholders in Connection with Sale of Aicuris to Asahi Kasei
Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc.
Firm News February 25, 2026
Gibson Dunn Advises Arcosa on $450 Million Sale of Arcosa Marine Products to Wynnchurch Capital
Gibson Dunn is advising Arcosa, Inc. on the sale of Arcosa Marine Products, Inc. to Wynnchurch Capital, L.P. for $450 million.